Dianthus Therapeutics Inc. has, appropriately, flowered in springtime. The Waltham, Mass.-based company emerged from stealth with $100 million in series A funding and lofty ambitions to rewrite the rules of targeting the complement system with a pipeline of antibodies that bring new levels of selectivity to an area of innate immunity that has proved difficult to target.

Researchers at the University of Pennsylvania have gained new insight into how different inflammatory conditions reinforce each other via trained innate immunity.

A handful of developers are advancing drug prospects in the localized scleroderma (LS) space, with candidate mechanisms that range from cell-based gene therapy to IL-4 or IL-6 antagonism to PDE4 blocking, and with efforts that involve approved as well as experimental compounds.

Screening a panel of potential autoantigens, investigators at the Karolinska Institute have identified four autoantigens that are targeted by the T cells of multiple sclerosis patients.

A new animal model of systemic lupus erythematosus (lupus) could be useful for understanding the disparity of the disorder, which is vastly more common in women than men.